- Home
- ENTA vs RAPT Comparison
ENTA vs RAPT Comparison
Compare ENTA & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- RAPT
- Stock Information
- Founded
- ENTA 1995
- RAPT 2015
- Country
- ENTA United States
- RAPT United States
- Employees
- ENTA N/A
- RAPT N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- ENTA Health Care
- RAPT Health Care
- Exchange
- ENTA Nasdaq
- RAPT Nasdaq
- Market Cap
- ENTA 164.6M
- RAPT 194.2M
- IPO Year
- ENTA 2013
- RAPT 2019
- Fundamental
- Price
- ENTA $8.28
- RAPT $16.22
- Analyst Decision
- ENTA Strong Buy
- RAPT Buy
- Analyst Count
- ENTA 4
- RAPT 5
- Target Price
- ENTA $22.25
- RAPT $33.60
- AVG Volume (30 Days)
- ENTA 158.9K
- RAPT 90.1K
- Earning Date
- ENTA 08-11-2025
- RAPT 11-11-2025
- Dividend Yield
- ENTA N/A
- RAPT N/A
- EPS Growth
- ENTA N/A
- RAPT N/A
- EPS
- ENTA N/A
- RAPT N/A
- Revenue
- ENTA $64,806,000.00
- RAPT N/A
- Revenue This Year
- ENTA N/A
- RAPT N/A
- Revenue Next Year
- ENTA $1.65
- RAPT N/A
- P/E Ratio
- ENTA N/A
- RAPT N/A
- Revenue Growth
- ENTA N/A
- RAPT N/A
- 52 Week Low
- ENTA $4.09
- RAPT $5.67
- 52 Week High
- ENTA $13.37
- RAPT $26.56
- Technical
- Relative Strength Index (RSI)
- ENTA 49.11
- RAPT 76.72
- Support Level
- ENTA $8.25
- RAPT $11.19
- Resistance Level
- ENTA $9.08
- RAPT $13.66
- Average True Range (ATR)
- ENTA 0.44
- RAPT 0.83
- MACD
- ENTA -0.08
- RAPT 0.44
- Stochastic Oscillator
- ENTA 3.78
- RAPT 93.52
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.